Insomnia

Perlis, Michael L.; Posner, Donn; Riemann, Dieter; Bastien, Célyne; Teel, Joseph; Thase, Michael E.

doi:10.1016/s0140-6736(22)00879-0

Cited by 156 publications

(90 citation statements)

References 112 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chronic conditions such as CVD, metabolic diseases and mood disorders may be associated with this progressive deterioration in people’s global health, and sleep problems can be a good indicator of such decline. This study confirms that sleep problems can present independently or alongside other medical conditions or mental health disorders and that it is a risk factor for developing these other disorders if not treated [ 32 ].…”

Section: Discussionsupporting

confidence: 77%

Sleep Problems and New Occurrence of Chronic Conditions during the COVID-19 Pandemic in the UK

Falkingham

Evandrou

Vlachantoni

et al. 2022

IJERPH

View full text Add to dashboard Cite

The COVID-19 pandemic has negatively impacted upon sleep health. Relatively little is known about how this may influence the population’s health subsequently. This prospective longitudinal study aims to examine the consequences of sleep problems for physical and mental health during the COVID-19 pandemic in the UK, using data from the Understanding Society: COVID-19 Study, a large-scale population-based survey with 12,804 adults aged 16 and above. A measure of sleep problems was derived from Pittsburgh Sleep Quality Index (PSQI) questions, reflecting seven dimensions of sleep quality. Binary logistic regressions were applied to investigate the relationship between sleep problem and the incidence of cardiovascular disease (CVD), hypertension, diabetes, obesity, arthritis and an emotional, nervous or psychiatric problem over the 15 months follow-up period. The analysis confirms that sleep problems are prevalent and vary between sub-groups among adults. Notably, sleep problems are then significantly associated with a higher risk of cardiovascular disease, hypertension, diabetes, obesity, arthritis and emotional, nervous or psychiatric problems, independent of demographic, socioeconomic, familial and health confounders. Our findings suggest promoting good sleep hygiene should be prioritised during the pandemic, and more generally as part of wider programmes aimed at promoting good physical and mental health.

show abstract

Section: Discussionsupporting

confidence: 77%

Sleep Problems and New Occurrence of Chronic Conditions during the COVID-19 Pandemic in the UK

Falkingham

Evandrou

Vlachantoni

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…In some cases, it may remit upon discontinuation of therapy, but symptoms may also worsen. CBT-I has demonstrated good durability of beneficial effects following discontinuation, but sustained improvement is less predictable with insomnia pharmacotherapy [ 104 ]. As such, we expect in many cases baseline insomnia symptoms will return following discontinuation of an insomnia therapy.…”

Section: Discussionmentioning

confidence: 99%

Alliance for Sleep Clinical Practice Guideline on Switching or Deprescribing Hypnotic Medications for Insomnia

Watson

Benca

Krystal

et al. 2023

JCM

View full text Add to dashboard Cite

Determining the most effective insomnia medication for patients may require therapeutic trials of different medications. In addition, medication side effects, interactions with co-administered medications, and declining therapeutic efficacy can necessitate switching between different insomnia medications or deprescribing altogether. Currently, little guidance exists regarding the safest and most effective way to transition from one medication to another. Thus, we developed evidence-based guidelines to inform clinicians regarding best practices when deprescribing or transitioning between insomnia medications. Five U.S.-based sleep experts reviewed the literature involving insomnia medication deprescribing, tapering, and switching and rated the quality of evidence. They used this evidence to generate recommendations through discussion and consensus. When switching or discontinuing insomnia medications, we recommend benzodiazepine hypnotic drugs be tapered while additional CBT-I is provided. For Z-drugs zolpidem and eszopiclone (and not zaleplon), especially when prescribed at supratherapeutic doses, tapering is recommended with a 1–2-day delay in administration of the next insomnia therapy when applicable. There is no need to taper DORAs, doxepin, and ramelteon. Lastly, off-label antidepressants and antipsychotics used to treat insomnia should be gradually reduced when discontinuing. In general, offering individuals a rationale for deprescribing or switching and involving them in the decision-making process can facilitate the change and enhance treatment success.

show abstract

“…Insomnia disorder is characterized by difficulty falling and/or staying asleep; it is further characterized by awakening earlier in the morning, with the inability to fall back to sleep at least 3 nights per week and for at least 3 months (4). Investigating this disorder is highly important for public health, since it is associated with more hospital visits and loss of workforce due to daytime sleepiness, fatigue, impairment in cognitive performance, and mood disturbances (3,(5)(6)(7).…”

Section: Introductionmentioning

confidence: 99%

Type D personality to insomnia: Sleep reactivity, sleep effort, and sleep hygiene as mediators

et al. 2023

View full text Add to dashboard Cite

BackgroundInsomniacs are heterogenous group with very diverse personalities. We aimed to investigate the mediating role of sleep reactivity (SR), sleep hygiene (SH), and sleep effort (SE) in the relationship between Type D personality and insomnia.Materials and methodsWe conducted a cross-sectional survey among 474 participants. The survey comprised the sociodemographic data form, Insomnia Severity Index (ISI), D Type Personality Scale (DS-14), Ford Insomnia Response to Stress Test (FIRST), Glasgow Sleep Effort Scale (GSES), and Sleep Hygiene Index (SHI). We conducted hierarchical multiple regression analysis to identify the associations between age, sex, SR, Type D personality traits, SE, SH, and insomnia severity. We subsequently conducted mediation analyses to examine whether SR, SH, and SE mediated the relationship between Type D personality and insomnia.ResultsISI, DS-14, FIRST, SHI, and GSES scores were significantly higher in individuals with Type D personality. Female sex, SR, Type D personality traits, SE, and SH explained 45% of the variance in insomnia severity. When age, sex, insomnia response to stress, and Type D personality traits were controlled, SE and SH significantly explained 25% of the variance in insomnia severity (R2 = 0.45, R2 change = 0.25, F (6.474) = 65.58, p < 0.001). SR, SE, and SH each played a partial mediating role between Type D personality and insomnia.ConclusionThe findings showed that individuals with Type D personality had high SR and that individuals with a higher number of these personality traits exhibited more severe insomnia symptoms through high SR, greater SE, and worse SH.

show abstract

Insomnia

Cited by 156 publications

References 112 publications

Sleep Problems and New Occurrence of Chronic Conditions during the COVID-19 Pandemic in the UK

Sleep Problems and New Occurrence of Chronic Conditions during the COVID-19 Pandemic in the UK

Alliance for Sleep Clinical Practice Guideline on Switching or Deprescribing Hypnotic Medications for Insomnia

Type D personality to insomnia: Sleep reactivity, sleep effort, and sleep hygiene as mediators

Contact Info

Product

Resources

About